CYCN Cyclerion: Net Assets per Single Share
Cyclerion Therapeutics (CYCN) is developing a pipeline of signaling molecule-based drugs for the regeneration of brain and kidney vessels. The book value per share illustrates the trend of net assets, with the value of 1.20 becoming the current benchmark. However, the narrowing of R&D to niche compounds and the risk of high capital burn given a limited portfolio pose serious threats to the business's financial stability.
Summary analytical data breakdowns for Cyclerion Therapeutics Inc. (CYCN)
- stock price and consensus target price:
- company stock capitalization data:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Cyclerion Therapeutics|CYCN - Long-Term Debt to Capital|Short-Term Debt to Equity Cyclerion|CYCN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Cyclerion Therapeutics, Inc.|CYCN - Long-Term Debt|Company Short-Term Debts Cyclerion Therapeutics|Quick Liquidity Indicator cyclerion.com
- earnings and multiples data:
General company analysis:CYCN - cyclerion.com
The assessment of the margin of safety for Cyclerion Therapeutics (CYCN) is based on the calculation of net equity minus liabilities per share, which determines the real value of the company's assets. By analyzing the book value per share chart, an investor can see the business's tangible foundation, which, in the case of a biotech, supports the development of unique sGC stimulators for the therapy of cognitive disorders.
Main competitors
Biogen Corp - Book Value per Share|Neurocrine Corp (NBIX) - Accounting Value per Share|Regencell Bioscience (RGC) - Net Assets per Single Share|Equity per Share AXSM|Net Assets per Single Share ACADIA Pharmaceuticals Inc.|Equity per Share XENE (Xenon Pharmaceuticals Inc.)|Book Value per Share VKTX|SUPN - Net Asset Value per Share|Catalyst Pharmaceuticals - Accounting Value per Share|Book Value per Share denalitherapeutics.com DNLI|HRMY - Net Assets per Single Share|Accounting Value of a Share BHVN (Biohaven Ltd)|Amylyx (AMLX) - Net Assets per Single Share|Net Asset Value per Share Trevi Corp (TRVI)|PRAX (Praxis Precision Medicines) - Book Value per Share|Accounting Value per Share anavex.com (AVXL)|Accounting Value per Share CBLL (CeriBell)|PRTA - Net Asset Value per Share|Book Value per Share ALEC (Alector)|ANNX - Accounting Value per Share|OMER - Net Assets per Single Share|NGNE: Net Assets per Single Share|ACIU: Book Value per Share|Net Asset Value per Share Voyager Therapeutics Inc (VYGR)|Net Assets per Single Share Neumora Therapeutics Inc|SCLX: Accounting Value of a Share|Book Value per Share TVGN|Net Assets per Share alphacognition.com|Net Assets per Single Share Cognition Therapeutics CGTX|Inhibikase Therapeutics Inc (IKT) - Net Asset Value per Share|SAVA - Net Assets per Single Share|ASRT (Assertio Holdings, Inc.) - Equity per Share|COYA (coyatherapeutics.com) - Accounting Value per Share|Vistagen - Accounting Value of a Share|Accounting Value per Share OVID|ABOS (Acumen Pharmaceuticals Inc.) - Book Price of a Share|Book Value per Share CRVO|ATHE (alteritytherapeutics.com) - Accounting Value of a Share|Book Value per Share CLNN (Clene)|PepGen Inc (PEPG) - Net Asset Value per Share|JUNS - Net Assets per Single Share|Accounting Value of a Share RLMD (Relmada Therapeutics Inc)|ANVS: Book Value per Share|Grace Therapeutics (GRCE) - Book Value per Share|Net Assets per Single Share Firefly Neuroscience, Inc|ANEW Medical, Inc. - Share Book Value|Book Value per Share NRSN|RVPH - Net Asset Value per Share|MetaVia - Accounting Value per Share|Book Value per Share NeurAxis Inc NRXS|HSDT: Accounting Value per Share|Passage Bio, Inc. - Book Price of a Share|NEUP: Book Value per Share|NERV - Net Assets per Share|ATHA (Athira) - Book Value per Share|Accounting Value per Share Addex (ADXN)|Net Assets per Single Share Alzamend Neuro, Inc. (ALZN)|Net Assets per Share protagenic.com|Book Value per Share KTTA (Pasithea Therapeutics Corp.)|CRGT - Accounting Value per Share|ATXI: Accounting Value per Share|Net Asset Value per Share BrainStorm Cell Therapeutics Inc.|CARA: Book Value per Share|Accounting Value per Share chromocell.com|Net Assets per Single Share Eliem Therapeutics, Inc.|Equity per Share ITCI (Intra-Cellular)|Net Assets per Single Share Longboard Pharma (LBPH)|Marinus Pharma - Equity per Share|Book Value per Share NKGN (NKGen Biotech, Inc.)|neurobopharma.com (NRBO) - Net Asset Value per Share|SAGE: Accounting Value per Share|SNPX - Book Value per Share|Trevena, Inc (TRVN) - Net Assets per Single Share|Vigil Neuroscience, Inc. - Accounting Value of a Share|Net Assets per Single Share Anew Medical|Net Asset Value per Share cerevel.com CERE